Table 3: Correlation of clinicopathologic parameters with VEGF-C, VEGFR-3, and CNTN-1 expression in gastric cancer ( /%).

Clinicopathological featuresTotal casesVEGF-CVEGFR-3CNTN-1
(+)(−)P (+)(−)P (+)(−)P

Age (ys)   0.925     0.972
  ≧6069/65.739/66.130/65.247/69.122/59.540/65.629/65.9
  <6036/34.320/33.916/34.821/30.916/40.521/34.415/34.1
Gender0.6760.5710.545
 Male73/69.542/71.231/67.446/67.627/73.041/67.232/72.7
 Female32/30.517/28.815/32.622/32.410/27.020/34.812/27.3
Tumor size0.1770.3170.035
  ≧5 cm58/55.236/61.022/47.840/58.818/48.639/63.919/43.2
  <5 cm47/44.823/39.024/52.228/41.219/51.422/36.125/56.8
Tumor location0.2180.3200.098
 Upper17/16.211/18.66/13.013/19.14/10.86/9.811/25.0
 Middle34/32.415/25.519/41.319/27.915/40.520/32.814/31.8
 Lower54/51.433/55.921/45.736/52.918/58.735/57.419/43.2
Lauren’s classification0.0710.8850.328
 Intestinal70/66.735/59.335/76.145/66.225/67.643/70.527/61.4
 Diffuse35/33.324/40.711/23.923/33.812/32.418/29.517/38.6
TNM stage0.001<0.0010.002
  I + II41/39.015/25.426/56.518/26.523/62.216/26.225/56.8
  III + IV64/61.044/74.620/43.550/73.514/37.845/73.819/43.2
Vascular invasion0.5260.1790.385
  (+)26/24.816/32.210/15.214/20.612/32.417/27.99/20.5
  (−)79/75.243/67.836/84.854/79.425/67.644/72.135/79.5
Serosa invasion0.3630.0840.148
  (+)37/35.223/39.014/30.428/41.29/24.318/29.519/43.2
  (−)68/64.836/61.032/69.640/58.828/75.743/70.525/56.8
Lymphatic invasion<0.001<0.0010.001
  (+)66/62.949/83.117/37.054/79.412/32.447/77.019/43.2
  (−)39/37.110/16.929/63.014/20.625/67.614/23.025/56.8
Lymph node metastasis<0.001<0.001<0.001
  (+)70/66.749/83.121/45.754/79.416/43.250/82.020/45.5
  (−)35/33.310/16.925/54.314/20.621/56.811/18.024/54.5